Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 2, 2025Immunological MedicineOpen Access

Effect of organism aging on the development of anti-PD-(L)1 therapy-associated adverse events

View Full Paper
Ask AI
Bookmark
Share

Authors

HTHirotake TsukamotoKMKosaku MurakamiYMYuji Miura

Discussion

Loading...

Member takes

Overview

This review explores aging effects on immune-related adverse events in patients receiving ICIs, suggesting management strategies.

Key Points

  • Chronological aging significantly influences the development of immune-related adverse events in patients receiving ICIs, highlighting a critical risk factor.
  • Older patients appear to experience a notably increased incidence of immune-related adverse events, emphasizing the importance of age in treatment outcomes.
  • This review employs various immunological perspectives to elucidate the relationship between aging and immune response toxicity, focusing on both cellular and chronological aging.
  • Insights from patient specimens and animal models underscore the need for strategic patient management to optimize cancer immunotherapy effectiveness across ages.

Cite This Study

Tsukamoto et al. (2025) studied this question.

synapsesocial.com/papers/68de8eaeaa6cec72c69ea865https://doi.org/10.1080/25785826.2025.2564474
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Age-related immune states and PD-1 blockade: mechanisms and strategies for the elderly2025
  2. 2Immune checkpoint inhibition in the context of aging2025
  3. 3Immunotherapy in older adults with gynecologic cancers: rethinking age as a limiting factor.2025
  4. 4Late-Onset Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy2025 · 53 citations
  5. 5Immunotherapies for Aging and Age-Related Diseases: Advances, Pitfalls, and Prospects.2025